Skip to content

This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Learn more

Radiopharmaceutical with tumor-targeting molecule and diagnostic radioisotope.

Revolutionizing Cancer Treatment: The Power of Theranostics in Oncology

Theranostics represents a concept in personalized medicine wherein the same or similar targeting molecules are used both for diagnostics and therapy.

In oncology, theranostics has acquired greater importance in recent years, as advanced, hard-to-treat tumors have been effectively treated with low side effects (Langbein T et al., 2019). It involves drugs termed radiopharmaceuticals, which usually occur as theranostic pairs, based on small molecule compounds or antibodies that target cell surface receptors overexpressed on tumor cells.

A radiopharmaceutical consists of a tumor-targeting molecule combined with a diagnostic or therapeutic radioisotope via a chelator. The great strength of the theranostics paradigm is the precise selection of patients, at the imaging stage, who will potentially benefit from the targeted radionuclide therapy (Turner JH 2018).

Take a look at the components of a typical radiopharmaceutical. Watch this video to learn more about their mode of action.

Radiopharmaceutical with tumor-targeting molecule and diagnostic radioisotope.

References:

  • Langbein, Thomas, Wolfgang A. Weber, and Matthias Eiber. 2019. “Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.” Journal of Nuclear Medicine 60(Supplement 2): 13S-19S. DOI: 10.2967/jnumed.118.220566

  • Turner, J Harvey. 2018. “An Introduction to the Clinical Practice of Theranostics in Oncology.” The British Journal of Radiology 91(1091): 20180440. DOI: 10.1259/bjr.20180440